Collectively, IFN-α antibodies and signaling inhibitors represent mechanistically grounded strategies for SLE-associated AS management, though definitive clinical validation requires large-scale trials to establish risk-benefit ratios across diverse patient populations. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.